Superworth

CRISPR Therapeutics EPS CRSP

Diluted earnings per share by quarter and over the last twelve months, from 2015.

Last 12 months, to Jun 30, 2026
−$4.76
Latest quarter, Q2 FY26
−$0.94
Fiscal year 2025
−$6.52

CRISPR Therapeutics' earnings per share was −$4.76 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.94.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$6.52n/a
FY2024−$4.37n/a
FY2023−$1.94n/a
FY2022−$8.37−289%
FY2021$4.42n/a
FY2020−$5.27−643%
FY2019$0.97n/a
FY2018−$3.43n/a
FY2017−$1.72n/a
FY2016−$6.93n/a
FY2015n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.94n/a−$4.76
Q1 FY26−$1.28n/a−$6.22
Q4 FY25−$1.37n/a−$6.52
Q3 FY25−$1.17n/a−$5.59
Q2 FY25−$2.40n/a−$5.43
Q1 FY25−$1.58n/a−$4.52
Q4 FY24−$0.44−139%−$4.37
Q3 FY24−$1.01n/a−$2.81
Q2 FY24−$1.49n/a−$3.21
Q1 FY24−$1.43n/a−$2.70
Q4 FY23$1.12n/a−$1.94
Q3 FY23−$1.41n/a−$4.47

Against its peers

Companies in Biotechnology nearest CRISPR Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
CRSPCRISPR Therapeutics−$4.76
KRYSKrystal Biotech$7.98+62% a year
ADMAAdma Biologics$0.70−18% a year
RGENRepligen$0.73
VCELVericel$0.46+283% a year
TECHBIO-TECHNE$1.15+150% a year
HALOHalozyme Therapeutics$3.35−23% a year
NBIXNeurocrine Biosciences$6.82+102% a year
EXELExelixis$3.18+53% a year
INCYIncyte$7.85+78% a year
UTHRUnited Therapeutics$27.95+9% a year
Peer median$3.27

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on CRISPR Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.